ask="5.00"
ask_size="9000"
average_daily_volume="51836"
bid="2.41"
bid_size="100"
book_value="1.19"
change="+0.01"
change_from_200_day_moving_average="-1.35"
change_from_50_day_moving_average="-0.45"
change_from_52_week_high="-3.82"
change_From_52_week_low="0.14"
change_in_percent="+0.38%"
close="2.65"
dividend_pay_date="N/A"
dividend_per_share="N/A"
dividend_yield="N/A"
earnings_per_share="-3.90"
ebitda="-15.74M"
eps_estimate_current_year="-3.71"
eps_estimate_next_quarter="0.00"
eps_estimate_next_year="-2.81"
ex_dividend_date="N/A"
float_shares="5652000"
high="2.70"
high_52_weeks="6.47"
last_trade_date="2/15/2017"
last_trade_price="2.65"
last_trade_size="100"
last_trade_time="3:59pm"
low="2.56"
low_52_weeks="2.51"
market_capitalization="16.68M"
moving_average_200_day="4.00"
moving_average_50_day="3.10"
name="MABVAX THERAPEUTICS"
notes="N/A"
one_year_target_price="18.00"
open="2.70"
pe_ratio="N/A"
peg_ratio="-0.01"
percent_change_from_200_day_moving_average="-33.76%"
percent_change_from_50_day_moving_average="-14.65%"
percent_change_from_52_week_high="-59.07%"
percent_change_from_52_week_low="+5.58%"
previous_close="2.64"
price_eps_estimate_current_year="N/A"
price_eps_Estimate_next_year="N/A"
price_per_book="2.21"
price_per_sales="18.35"
revenue="905615.00"
shares_outstanding="6296000"
short_ratio="7.82"
stock_exchange="NCM"
symbol="MBVX"
volume="30638"
weeks_range_52="2.51 - 6.47"
